Teva (TEVA) calls active after patent board says certain claims of Copaxone patent invalid
- Stocks dip as earnings pour in, consumer discretionary lags
- UPDATE: Alphabet (GOOG) Tops Q3 EPS Views; Revs Strong
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
- Cirrus Logic, Inc. (CRUS) Q2 Results and Guidance Beat Estimates
- Amazon.com (AMZN) Misses Q3 EPS by 26c, Offers Q4 Guidance
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Teva Pharma (NYSE: TEVA) August 55 and 57.50 calls are active on total call volume of 25K contracts (15K puts) after the U.S. Patent and Trademark Office's Patent Trial and Appeal Board, or PTAB, determined that Mylan Pharmaceuticals (MYL) and Amneal Pharmaceuticals, as co-petitioners, met their "burden of proving the unpatentability of claims 1-20 of '250 patent by a preponderance of the evidence." August call option implied volatility is at 47, September is at 38; compared to its 52-week range of 16 to 49.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Exxon Mobil (XOM) weekly option implied volatility increases to 37 into Q3 and outlook
- Stocks with Implied Volatility Movement
- Tesla (TSLA) volatility comes in as shares rally on Q3 results and outlook